According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -38.8% and a 12.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Immutep is a Moderate Buy with an average price target of $8.00.
Immutep’s market cap is currently $251.7M and has a P/E ratio of -10.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Read More on IMMP: